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Introduction
Hereditary spastic paraplegias (HSPs) are heterogeneous neurodegenerative disorders characterized by progressive spasticity of the lower limbs due to axonopathy of the corticospinal neurons. Clinically, HSPs are classified into pure and complicated forms, the latter being associated with additional neurological or non-neurological symptoms. Mutations in over 60 genes are implicated in HSP, although these only explain $30-70% of cases depending on the mode of inheritance (Finsterer et al., 2012; Fink, 2013; Crow et al., 2014; Lo Giudice et al., 2014; Schule et al., 2016) . Recent gene discoveries have revealed a genetic overlap between HSP and a spectrum of neuronopathies and axonopathies (Peeters et al., 2013) , supporting their clinical similarity and common pathomechanistic background.
ATP13A2 (OMIM 610513 ) is a lysosomal P5-type transport ATPase, for which the transported substrate remains unidentified (van Veen et al., 2014) . ATP13A2 undergoes catalytic autophosphorylation on Asp508 within the conserved P-type ATPase motif, which is regulated by phosphatidic acid and phosphatidylinositol(3,5)-bisphosphate Martin et al., 2015) . ATP13A2 offers cellular protection to heavy metal ions (Mn 2+ , Fe 3+ , Zn 2+ ) (Gitler et al., 2009; Schmidt et al., 2009; Tan et al., 2011; Covy et al., 2012; Park et al., 2014; Rinaldi et al., 2015; Martin et al., 2016) , -synuclein (Gitler et al., 2009; Schultheis et al., 2013; Kong et al., 2014) and mitochondrial toxicity (Grunewald et al., 2012; Gusdon et al., 2012; Holemans et al., 2015; Park et al., 2015; Martin et al., 2016) . All of these functions depend on the capability of ATP13A2 to undergo autophosphorylation (Gitler et al., 2009; Schmidt et al., 2009; Tan et al., 2011; Covy et al., 2012; Park et al., 2014; Rinaldi et al., 2015) .
Mutations in ATP13A2 have been initially associated with Kufor-Rakeb syndrome (KRS) , an autosomal recessive form of juvenile-onset parkinsonism that is typically accompanied by cognitive impairment, supranuclear gaze palsy and signs or symptoms of pyramidal degeneration. Reports of brain iron accumulation in the putamen and caudate present in some patients have also led to classification of KRS as a form of neurodegeneration with brain iron accumulation (NBIA) (Behrens et al., 2010; Schneider et al., 2010) . Subsequent studies have broadened the phenotypic spectrum of biallelic ATP13A2 mutations to include also milder cases without pyramidal or cognitive involvement (Di Fonzo et al., 2007) . Additionally, single heterozygous ATP13A2 variants may represent risk factors for early-and late-onset parkinsonism Rakovic et al., 2009; Fei et al., 2010; Park et al., 2015) .
More recently, ATP13A2 mutations were identified in a single kindred with neuronal ceroid lipofuscinosis (NCL) (Farias et al., 2011; Bras et al., 2012; Schultheis et al., 2013) , histologically defined by the presence of vacuolated lymphocytes, cytoplasmic positive autofluorescent lipopigments and fingerprint-like profiles in nerve and muscle biopsy (Tome et al., 1985) . The clinical presentation in this family showed strong overlap with KRS and was characterized by combined extrapyramidal, pyramidal and cerebellar involvement, accompanied by cognitive deficits, peripheral neuropathy and slow vertical eye movements (Bras et al., 2012) .
Here, we report that mutations in ATP13A2 cause complicated HSP type SPG78, further expanding the clinical and genetic spectrum of ATP13A2-associated disorders, which are commonly characterized by lysosomal and mitochondrial dysfunction. We propose that loss of ATP13A2 autophosphorylation activity contributes to the loss of ATP13A2 function and disease aetiology.
Materials and methods

Clinical and imaging evaluation
All patients received a systematic neurological and electrophysiological assessment to evaluate affection of multiple neurological systems by movement disorder specialists.
Routine brain MRI including T 1 -, T 2 , diffusion-weighted images (DWI) and fluid attenuated inversion recovery T 2 (FLAIR) images were performed in all five cases and reviewed by neuroradiologists and neurologists. Dopamine transporter scintigraphy (DaTSCAN) with 185 MBq 123 I-Ioflupan was performed in Patient HIH21480.II.3. Images were acquired with a dual-headed SPECT camera (E.CAM + , Siemens Healthcare) at 180 min after bolus injection of 185 MBq 123 I-FP-CIT (GE Healthcare Buchler). Image reconstruction was performed using an iterative algorithm (2D Ordered Subset Expectation Maximization, three iterations, eight subsets). Images were interpreted both visually and quantitatively with the Hermes Brass software package (Version 3.4.4, Hermes Medical Solutions, Stockholm, Sweden).
Written informed consent was obtained from all patients and the study was approved by the respective local institutional review boards.
Whole exome sequencing and homozygosity mapping
Genomic DNA was isolated from peripheral blood according to standard procedures. The exomes of Patients HSP84.II.1, HSP84.II.3, HIH21480.II.3 and HIH22132.II.1 were captured by Agilent's SureSelect Enrichment solution. Paired-end sequencing on Hiseq2000/2500 platforms yielded $6 Gb of raw data, with 90% of the targets covered at least 20 Â. The sequencing reads were aligned to hg19 with the BurrowsWheeler aligner (Li and Durbin, 2009) . Variant calling and realignment was done by GATK (McKenna et al., 2010) , subsequent annotation and filtering were performed with GenomeComb package for genomic data analysis (Reumers et al., 2012) (for Patients HSP84.II.1 and HSP84.II.3) and Genesis (Gonzalez et al., 2015) (for Patients HIH22132.II.1 and HIH21480.II.3).
Homozygosity mapping was performed using SNPs extracted from whole exome sequencing data using the HOMWES tool in GenomeComb (Kancheva et al., 2015) .
Sanger sequencing and genetic validation
Identified variants were validated by bidirectional Sanger sequencing. The PCR products were purified with ExoSAP-IT Õ (USB), directly sequenced with a BigDye Õ Terminator v.3.1 kit (Applied Biosystems) and electrophoretically separated on an ABI3730xl DNA Analyzer (Applied Biosystems).
Co-segregation analysis of the variants with the disease was performed for all available family members. The novel mutations were screened in unrelated control individuals.
Genetic nomenclature
Mutations were described according to the Human Genome Variation Society nomenclature; transcript ATP13A2 (NM_001141973.2) was used as a reference.
DNA constructs
The hATP13A2-pDONR221 was previously described . Via Gateway subcloning ATP13A2 was transferred into pcDNA6- GFP-tag (N-terminal) 
Western blotting
Western blotting was performed as previously described (Vandecaetsbeek et al., 2009) . Membranes were probed with anti-ATP13A2 rabbit polyclonal antibody (1:5000, A3361, Sigma). Detection was performed via enhanced chemiluminescence (Pierce), which was visualized by a Bio-Rad ChemiDoc TM MP imager.
Cell cultures
Control, Thr512Ile and Phe851Cysfs Ã 6 fibroblasts were maintained in BME media (Sigma), supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, at 37 C, 5% CO 2 . HeLa and COS-1 cells were maintained in Dulbecco's modified Eagle medium containing 10% foetal calf serum, 4 mM GlutaMAX TM -I supplement, 100 U/ml penicillin, 100 mg/ml streptomycin and 0.1 mM minimal essential medium non-essential amino acids (Invitrogen) at 37 C in an atmosphere of air with 5% CO 2 .
Immunocytochemistry and fluorescence microscopy
Fibroblasts, COS-1 or HeLa cells were seeded on glass-bottomed dishes and their lysosomes and mitochondria were visualized with LysoTracker Õ or MitoTracker Õ probes according to the manufacturer's instructions (Life Technologies). Additionally, control and Thr512Ile fibroblasts were seeded on 12 mm diameter cover slips and 48 h later fixed with icecold methanol for 20 min at À20
C. Subsequently, the cells were stained with anti-LAMP1 rabbit polyclonal antibody (1:500, ab24170, Abcam), anti-TOMM20 mouse monoclonal antibody (1:500, ab56783, Abcam), and secondary anti-rabbit IgG Alexa Fluor Õ 488 and anti-mouse IgG Alexa Fluor Õ 594 antibodies (1:500, Life Technologies).
HeLa cells were transiently transfected with GFP-N-ATP13A2 WT or Phe177Leu, Thr512Ile, Gln1135 Ã using Lipofectamine Õ LTX reagent (Life Technologies), cultured on glass-bottomed dishes for 48 h, and stained with LysoTracker Õ (Life Technologies).
HeLa cells were transiently co-transfected with GFP-N-ATP13A2 WT or mutants Phe177Leu, Thr512Ile and Gln1135
Ã together with pCI-mRuby-KDEL (ER marker) using Lipofectamine Õ LTX reagent (Life Technologies). Cells were cultured on glass-bottomed dishes for 48 h and fluorescent images were taken using a Zeiss LSM700 confocal microscope.
Lysosomal area and mitochondrial morphology
Lysosomal area ratio was measured in control and patientderived LysoTracker Õ -stained fibroblasts (Thr512Ile-HSP) using ImageJ software . The transmitted light image was used to manually delineate the cell borders, and for each cell the area covered with lysosomes was segmented based on automatic intensity thresholding (Huang method). Lysosomal area ratio was calculated by dividing the lysosomal area by the total cell area for each cell. More than 50 cells per genotype were analysed.
To compare mitochondrial morphology between control and Thr512Ile-HSP ATP13A2 we quantitatively assessed mitochondrial morphology in fibroblasts stained with MitoTracker Õ . Mitochondria were automatically detected using an ImageJ script with a customized segmentation procedure, which combines global (Triangle method) and local (Phansalkar method) automatic intensity thresholding, size-selective Watershed algorithm and Boolean operations on the binary masks. The shape factor (circularity) of over 30 000 individual mitochondrial segments originating from more than 200 cells was measured.
Lysosomal and mitochondrial homeostasis
Thr512Ile-HSP, Phe851Cysfs
Ã 6 and control fibroblasts were seeded in 12-well plates and allowed to adhere overnight at 37 C. For mitochondrial functionality, cells were stained with MitoTracker Õ Deep RED FM (1 mM) or tetra-methylrhodamine (TMRM, 1 mM) for 30 min. Pretreatment with carbonyl cyanide m-chlorophenyl hydrazone (CCCP, 1 mM) for 1 h prior to staining was used as a positive control ( Supplementary Fig.  1A ). For lysosomal functionality cells were stained with either LysoTracker Õ RED (1 mM) for 1 h or DQ-BSA (1 mM) for 2 h. Lysosomal function was monitored by the addition of Bafilomycin A1 (Baf A1, 10 nM) at least 1 h prior to staining ( Supplementary Fig. 1B ). Measurements for lysosomal and mitochondrial mass were normalized to cell size whereby forward scatter was used as a cell-size index. All samples were detected using an Attune flow cytometer (Becton Dickinson Immunocytometry systems).
Transmission electron microscopy of human fibroblasts
Thr512Ile-HSP and control fibroblast primary cultures grown on glass cover slips were fixed in 4% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) for 4 h at room temperature followed by fixation over night at 4 C. After washing, cells were subsequently dehydrated through a graded ethanol series, including a bulk staining with 1% uranyl acetate at the 50% ethanol step followed by embedding in Spurr's resin. Ultrathin sections of a gold interference colour were cut using an ultra-microtome (Leica EM UC6), followed by a post-staining in a Leica EM AC20 for 40 min in uranyl acetate at 20 C and for 10 min in lead stain at 20 C. Sections were collected on Formvar-coated copper slot grids. Grids were viewed with a JEM 1400plus transmission electron microscope (JEOL) operating at 60 kV.
Membrane fractionation
COS-1 cells were transiently transfected with GFP-N-ATP13A2 WT or Phe177Leu, Thr512Ile, Gly528Arg, Gln1135 Ã using GeneJuice Õ (Novagen) according to the manufacturer's protocol. Forty-eight hours post-transfection, cells were harvested and fractionated as previously described (Vandecaetsbeek et al., 2009) . To prepare total membrane fractions, the lysates were first cleared from the nuclear fraction (1000g, 10 min, 4 C) and then centrifuged to collect the total membranes (200 000g, 35 min, 4 C). Fractions were suspended in 0.25 M sucrose with SIGMAFAST TM protease inhibitor cocktail (Sigma). Protein concentration was determined with the Q-bit fluorimetric method (Life Technologies).
Proteasome inhibition
COS-1 cells were transiently transfected with GFP-N-ATP13A2 WT or Phe177Leu, Thr512Ile, Gly528Arg, Gln1135 Ã using GeneJuice Õ (Novagen) according to the manufacturer's protocol. MG132 (M7449, Sigma-Aldrich) was dissolved in dimethyl sulphoxide (DMSO) solution buffer and used at 20 mM for 6 h. DMSO was used as a control vehicle.
Autophosphorylation assay
Forty micrograms of COS-1 membranes were added to a final volume of 95 ml of EP reaction buffer (17 mM HEPES pH 6.5, 160 mM KCl, 2 mM MgCl 2 , 1 mM DTT, 5 mM NaN 3 ). The reaction was initiated by addition of -32 P-ATP (7.5 mCi) in a final ATP concentration of 5.125 mM and stopped after 60 s by adding 400 ml ice-cold stop solution (20% trichloroacetic acid, 10 mM phosphoric acid). After precipitation on ice for 20 min, samples were centrifuged at 20 000g (30 min, 4 C). The pellet was washed twice with 400 ml ice-cold stop solution and dissolved in sample buffer (10% LDS, 10 mM NaH 2 PO 4 , 0.01% SDS, 10 mM 2-mercaptoethanol, 0.5 mg/ml bromophenol blue) prior to acidic electrophoresis, as previously described (Sorensen et al., 2012) .
Statistics
Analysis of lysosomal and mitochondrial quantification and function in control versus Thr512Ile-HSP or Phe851Cysfs
Ã 6 patient-derived fibroblasts was performed using a two-sample t-test. Relative expression levels and autophosphorylation in ATP13A2 WT and mutants were analysed using an ANOVA test with post hoc Bonferroni correction. All tests were twotailed and the level of significance was set at P 5 0.05.
Results
Identification of HSP-associated mutations in ATP13A2
We studied a Bulgarian family with three affected brothers (Family HSP84, Fig. 1A ) presenting an adult-onset HSP phenotype, complicated by mild cognitive impairment, cerebellar ataxia, and axonal motor and sensory polyneuropathy (Table 1) . Whole exome sequencing was performed on Patients HSP84.II.1 and HSP84.II.3, followed by whole exome sequencing-based homozygosity mapping. A total of 75 shared autozygous regions were identified, encompassing 111 Mb of genomic DNA. The whole exome sequencing data were filtered for homozygous variants located within these regions with an impact on protein structure (non-synonymous and/or affecting mRNA splicing) and 45% frequency in dbSNP135 (Sherry et al., 2001) , EVS6500 [Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA (URL: http://evs.gs. washington.edu/EVS/) (August 2014)], 1000 Genomes (Genomes Project et al., 2015) , and in-house exome/ genome databases (Gonzalez et al., 2015) . Only one missense variant, c.1535C 4 T (p.Thr512Ile) in ATP13A2 fulfilled these criteria. This variant co-segregated with the disease (Fig. 1A ) and was absent in 94 ethnically matched controls. The p.Thr512Ile substitution (p.Thr512Ile-HSP) targets a highly conserved amino acid (GERP score = 5.6) (Cooper et al., 2005) , affecting a residue in the autophosphorylation motif (Fig. 1B) , and is predicted to be deleterious by SIFT (Kumar et al., 2009 ), MutationTaster2 (Schwarz et al., 2014) and PolyPhen-2 (Adzhubei et al., 2010) . Surprisingly, the same mutation had previously been described to cause KRS in a sporadic Lebanese patient (p.Thr512Ile-KRS; nomenclature in original publication: NM_022089.2: c.1550C 4 T, p.Thr517Ile) (Dehay et al., 2012; Grunewald et al., 2012; .
To obtain additional genetic evidence on the causal link between ATP13A2 and HSP, we screened a cohort of 795 index cases with phenotypes overlapping the clinical manifestation in Family HSP84. This cohort comprised cases with pure or complicated HSP, ataxia and axonal neuropathy (Supplementary Table 1 ). To test the specificity of ATP13A2 mutations for this phenotypic spectrum, we additionally screened 1985 patients with autosomal recessive non-overlapping neurological and non-neurological phenotypes including cases with late-onset Alzheimer's disease, amyotrophic lateral sclerosis, epileptic encephalopathy, cardiomyopathy, deafness and ocular phenotypes (Gonzalez et al., 2015) .
Among the 795 cases with overlapping phenotypes we identified two additional families with autosomal-recessive complicated HSP and ATP13A2 mutations, while no biallelic mutations were found in the non-overlapping neurological and non-neurological phenotypes. A homozygous c.364C 4 T (p.Gln122 Ã ) variant was found in a Serbian family (HIH21480). This nonsense mutation introduces a premature stop codon in the fifth exon of ATP13A2. In the Bosnian HIH22132 family, two nonsense mutations
Ã )] were confirmed by Sanger sequencing (Fig. 1A) .
Clinical findings
The disease presentation in all five cases was dominated by an adult onset (mean 32 years) combined pyramidal-cerebellar syndrome that led to the clinical diagnosis of complicated HSP, which progressed rapidly (Table 1) . Cognitive deficits were present in four of five cases but ranged from very mild deficits to advanced dementia with fronto-temporal characteristics (Patient HIH22132.II.1). Supranuclear gaze palsy was noted in two cases. Nerve conduction studies revealed predominantly axonal sensory-motor peripheral neuropathy in four out of five individuals. Only one of the five cases showed clinical indication of extrapyramidal involvement in the form of very mild bradykinesia and slight resting tremor (Patient HIH22132.II.1) that didn't interfere with the activities of daily living.
The most striking finding on MRI was a progressive vermian and hemispheric cerebellar atrophy ( Fig. 2A-C) , accompanied by a less pronounced cortical atrophy and mild periventricular white matter changes in some cases. In two cases (Patients HSP84.II.3 and HIH22132.II.1) an 'ear of the lynx' sign (Riverol et al., 2009) and T 2 hyperintensities of the anterior fornix of the corpus callosum were noted ( Fig. 2A and B) . In one case (Patient HIH21480.II.3) thinning of the corpus callosum, periventricular white matter changes and a hydrocephalus internus were additionally present (Fig. 2C) . Prompted by the identification of ATP13A2 mutations, we performed a DaTSCAN ( 123 I-FP-CIT) in Patient HIH21480.II.3 to evaluate presynaptic dopamine transporter density in the striatum (Fig. 2D) . Although Patient HIH21480.II.3 showed no clinical signs or symptoms of extrapyramidal involvement, the DaTSCAN revealed a drastic decrease of dopamine transporter density, most pronounced in the putamen.
Functional evaluation of HSP-associated ATP13A2 mutations
In fibroblasts of a known KRS patient, the p.Thr512Ile-KRS mutation affects both lysosomal function and mitochondrial network integrity (Dehay et al., 2012; Grunewald et al., 2012; . Since we now identified the same mutation in patients with complicated HSP (p.Thr512Ile-HSP), we evaluated fibroblasts isolated from Patient HSP84.II.2. Lysosomes in patient and control fibroblasts were visualized by the lysosomal markers LysoTracker Õ (Fig. 3A) and LAMP1 (Supplementary 2 ). Compared to controls, we observed a significant increase in the amount of lysosomes per cell (Fig. 3A) , as seen before in fibroblasts from the Thr512Ile-KRS patient (Dehay et al., 2012) . Furthermore, via LysoTracker Õ Redbased flow cytometry we detected an increase in lysosomal mass in Thr512Ile-HSP compared to control fibroblasts (Fig. 3B) . The lysosomal functionality was also compromised, as there was a significant reduction in the proteolytic activity, which was assessed by the capability of processing the DQ-BSA substrate into a fluorescent product (Fig. 3C) . A similar lysosomal phenotype was also observed in fibroblasts derived from a KRS patient carrying a known truncating p.Phe851Cysfs Ã 6 mutation in ATP13A2 (Fig.  3B and C) (Crosiers et al., 2011) .
The mitochondrial network in the Thr512Ile-HSP and control fibroblasts was visualized using the mitochondrial markers MitoTracker Õ and TOMM20 ( Fig. 3D and Supplementary Fig. 2) . In contrast to the findings of Grunewald et al. (2012) , mitochondrial fragmentation or swelling was not markedly present in patient fibroblasts. Also a quantitative comparison of mitochondrial circularity did not reveal differences in mitochondrial morphology between patient-derived and control cells. However, fibroblasts carrying p.Thr512Ile-HSP mutation displayed a , and mitochondrial circularity is shown on the right. (E) We used the mitochondrial-specific dye MitoTracker Õ Deep RED FM, which binds mitochondrial membrane independently of the membrane potential, and thus staining intensity has been considered an index of mitochondrial mass (MFI, mean fluorescence intensity). (F) Tetra-methylrhodamine (TMRM, 1 mM) treatment for quantifying changes in mitochondrial membrane potential. For A and D data are represented by average AE standard error of the mean. For B, C, E and F data are represented by average AE SD.
§ t-test P = 0.009, ** P 5 0.05; *** P 5 0.001; NS = not significant. Scale bar = 10 mm.
significant increase in mitochondrial mass with an overall reduction in mitochondrial membrane potential ( Fig. 3E and F), in line with a previous report (Grunewald et al., 2012) . Ultrastructural analysis of Thr512Ile-HSP fibroblasts confirmed an excessive accumulation of lysosomes compared to control cells (Fig. 4A and B) . Strikingly, the majority of the lysosomes in Thr512Ile-HSP cells contained abnormal storage material consisting of whirls and stacks of membranes ( Fig. 4C-F) , a lysosomal content that was almost never observed in control cells (Fig. 4G) .
Known recessive mutations in ATP13A2 causing KRS are considered to be loss-of-function alleles. Some of them lead to aberrant transcripts, which are destroyed by compared to controls (B). The majority of lysosomes contain aberrant storage material consisting of whirls and stacks of membranes (C), in some cases forming fingerprint bodies (D) or large clusters of membrane containing vesicles (E). In addition, cytoplasmic inclusions of tightly packed membranes were frequently observed (F). In contrast, the content of lysosomes in control fibroblasts consisted of a normal mix of material (G). Scale bars = 500 nm, except in F = 100 nm.
nonsense-mediated mRNA decay (NMD), while others impair protein stability, leading to mislocalization of ATP13A2 to the endoplasmic reticulum and proteasomal degradation Park et al., 2011 Park et al., , 2014 Dehay et al., 2012; Podhajska et al., 2012; . p.Gln122 Ã and p.Arg444 Ã are predicted to be null alleles that are most likely prone to NMD, whereas the p.Gln1135
Ã may potentially escape NMD. This mutation lies in the last exon and likely leads to a truncated protein lacking 40 C-terminal amino acid residues. In contrast, according to in silico predictions the missense p.Thr512Ile mutation may have little impact on protein folding/stability (Phyre2; Kelley et al., 2015) .
To assess stability of the ATP13A2 mutants in vitro, COS-1 cells were transiently transfected with constructs allowing expression of wild-type, Thr512Ile or Gln1135
Ã followed by analysis of the levels of mutant proteins. We compared the HSP mutants to previously identified KRS mutant with compromised (Phe182Ile) ATP13A2 stability or early-onset parkinsonism mutant with preserved (Gly528Arg) ATP13A2 stability (Fig. 5A ). All wild-type and mutant ATP13A2 forms were successfully expressed, although reduced protein levels were observed for Phe177Leu, in line with an earlier report (Fig. 5A) . Putative degradation of the ATP13A2 mutants through the proteasomal pathway was evaluated using the proteasomal inhibitor MG132 (Fig. 5B) . Protein levels of all ATP13A2 variants increased upon MG132 treatment, suggesting partial breakdown by the proteasome. However, the per cent difference in expression levels between non-treated and MG132 conditions were similar for wild-type as for all mutant constructs.
As the p.Thr512Ile substitution targets a residue within the autophosphorylation motif (Fig. 1B) , we questioned its effect on autophosphorylation activity. We compared the autophosphorylation levels of wild-type and disease mutants in total membrane fractions of transiently transfected COS-1 cells (Fig. 5C and D) . In contrast to wild-type and Gly528Arg, the Thr512Ile protein was unable to undergo autophosphorylation, although it was expressed to comparable levels ( Fig. 5A and D) . In addition, we could not detect an autophosphorylation signal for Gln1135 Ã (Fig. 5C ) even when we increased the loading to reach comparable protein levels of wild-type and Gln1135
Ã (data not shown). No signal was observed for the Phe177Leu mutant, but this can be attributed to the weak expression levels and/or a loss of autophosphorylation activity (Fig. 5D) .
Finally, we evaluated the subcellular localization of the GFP-N-ATP13A2 mutants transiently expressed in HeLa cells ( Fig. 5E and Supplementary Fig. 4 ). We first confirmed that wild-type ATP13A2 co-localizes with LysoTracker Õ -labelled vesicles, whereas the KRS mutant Phe177Ile is mislocalized to the endoplasmic reticulum . The two novel HSP mutants were also mislocalized to the endoplasmic reticulum, as we observed co-localization of mutant proteins with the endoplasmic reticulum marker pCI-mRuby-KDEL (Supplementary Fig. 3 ). This suggests that, besides protein instability and inactivity, also mistargeting contributes to the loss-of-function of ATP13A2 in complicated HSP and KRS.
Discussion
Clinical spectrum of ATP13A2-related diseases Loss of ATP13A2 function has been linked to KRS, an early-onset atypical form of Parkinson's disease with dementia that has been considered among the NBIA syndromes (Micheli et al., 2006; Ramirez et al., 2006; Djarmati et al., 2009; Rakovic et al., 2009) , and the lysosomal storage disorder NCL (Bras et al., 2012) . Here, we report three novel nonsense and one missense mutations in ATP13A2 in three families diagnosed with complicated HSP for which we demonstrate loss of functionality. Clinically, the HSP phenotype associated with ATP13A2 mutations (SPG78) is reminiscent of the phenotype described for SPG11/15 and SPG48, with spastic paraplegia, cerebellar ataxia, cognitive deficits and axonal neuropathy being common features in both SPG78 and SPG11/15/48. Of note, SPG11/15 and SPG48 also frequently display extrapyramidal disease manifestations (Anheim et al., 2009; Schicks et al., 2011; Hirst et al., 2016) . The 'ear of the lynx' sign (T 2 hyperintensity of the anterior fornix of the corpus callosum), an imaging feature described for SPG11 (Riverol et al., 2009) and SPG48 (Hirst et al., 2016) , was also identified in two of five SPG78 cases in our study. However, the age of onset appears to be later in SPG78, neither lenticular nor retinal abnormalities were noted in SPG78, and thinning of the corpus callosum, a hallmark imaging finding in SPG11, 15 and 48 was present in only one of our cases.
When considered from a clinical diagnostic standpoint, the phenotypes associated with ATP13A2 mutations-KRS, NCL and HSP-appear independent, but this standpoint is now challenged by the discovery of a common genetic aetiology, i.e. loss-of-function mutations in overlapping regions or even identical sites in ATP13A2 (Fig. 6A) .
KRS, HSP and NCL were each defined before their respective genetic basis was uncovered. Despite being multisystemic and thus clinically complex disorders, they were classified according to their most striking feature. The prominent parkinsonism seen in KRS families due to mutations in ATP13A2, led to the classification as an earlyonset Parkinson's syndrome (PARK9) (Micheli et al., 2006; Ramirez et al., 2006; Djarmati et al., 2009; Rakovic et al., 2009) . Additionally, the KRS phenotype is considered to be part of the NBIA spectrum of disease due to the presence of iron accumulation in the putamen and caudate of at least a subset of cases (Schneider et al., 2013) . The discovery of lipopigment inclusions in another family with ATP13A2 mutations, which were also seen in mice and dogs with ATP13A2 loss of function (Farias et al., 2011; Schultheis et al., 2013) , led to the classification as NCL (CLN12). Here, we report that in three families with loss of ATP13A2 function lower-limb predominant spastic paraparesis is by far the most prominent clinical feature and thus, the disease was classified as an HSP and termed SPG78 (preliminary) (Gray et al., 2015) . mutations diverge remains unclear. Of interest, the same p.Thr512Ile substitution that causes a complicated HSP phenotype has previously been identified in a Lebanese KRS patient (Dehay et al., 2012; Grunewald et al., 2012; , suggesting that the mutation type is not the sole determinant of the clinical phenotype. The Lebanese KRS patient presented with rapidly progressive parkinsonism, supranuclear gaze palsy, perioral myokymia, Figure 6 Clinical spectrum of ATP13A2 mutations. (A) Schematic representation of the genomic and protein lay out of ATP13A2 and location of currently known disease-associated mutations. Topology of ATP13A2 represents 10 transmembrane domains (1-10) and an additional membrane-associated segment in the N-terminus (a). In black, mutations associated with KRS; in green, mutations associated with early-onset parkinsonism (EOPD); in blue, mutation associated with NCL; in red, mutations identified in this study, which are associated with complicated HSP. (B) Schematic representation of the neuronal systems affected by ATP13A2 dysfunction and resulting signs and symptoms apparent on a clinical level. Loss of ATP13A2 function in the cortex, extrapyramidal system, brainstem, pyramidal system, cerebellum, and the peripheral nerves leads to a variety of signs and symptoms including dementia, parkinsonism, vertical gaze palsy, spasticity, ataxia, and peripheral neuropathy. Predominance of extrapyramidal involvement or spasticity has led to the classification of ATP13A2-related disease as parkinsonism or HSP, respectively. We hypothesize that other carriers of ATP13A2 mutations might display predominance of other ATP13A2-dependent systems and therefore manifest as cerebellar ataxia, dementia or Charcot-Marie-Tooth disease.
and cognitive decline at the age of 44 years. Notably, as described in previously reported KRS patients (Williams et al., 2005) and personal observation in the original Chilean family , this patient also had pyramidal involvement with marked spasticity and hyperreflexia, most pronounced in the lower limbs, but no ataxia. It is clear that much is yet to be learned about which additional factors-genetic or environmentalcontribute to the individual presentation of disease in these families. Nevertheless, under the surface of the seemingly disparate clinical diagnostic classification of ATP13A2-related disease into the categories of parkinsonism/NBIA, NCL or HSP, the phenotypic features associated with ATP13A2 deficiency actually converge. Affection of various regions and/or systems of the nervous system (cortical, pyramidal, extrapyramidal, brainstem, cerebellar and peripheral) by loss of ATP13A2 function translates phenotypically into a multidimensional spectrum of associated signs and symptoms including dementia, spasticity, parkinsonism, disturbance of the saccadic eye movement system, ataxia, and peripheral neuropathy (Fig. 6B) . The quantitative expression, not the qualitative presence of these features has historically led us to determine diagnosis. While this approach may still be useful in clinical practice for pragmatic reasons, rigid diagnostic classification systems may hamper identification of the underlying genetic cause. Thinking outside the box of diagnostic classifications is needed to recognize genes associated with more fluid, multidimensional phenotypes like ATP13A2, PNPLA6 (Synofzik et al., 2014) , VCP (Kazamel et al., 2016) , BICD2 (Neveling et al., 2013; Oates et al., 2013; Peeters et al., 2013) , SPG11 (Guidubaldi et al., 2011; Daoud et al., 2012; Montecchiani et al., 2016) , DYNC1H1 (Vissers et al., 2010; Weedon et al., 2011; Harms et al., 2012) , TUBB4 (Erro et al., 2015) , SYNE1 (Synofzik et al., 2016) and others. We predict that the increasing use of unbiased and 'modular' methods for phenotyping, e.g. by application of the Human Phenotype Ontology (Kohler et al., 2014) , in combination with unbiased genetic screening methods such as whole exome and whole genome sequencing will uncover many more Mendelian disease spectra crossing historically defined diagnostic categories in the future.
Several ATP13A2 HSP and KRS mutants are mistargeted, unstable and/or inactive As in previous studies (Dehay et al., 2012; Grunewald et al., 2012; Podhajska et al., 2012; , we confirm that the loss-of-function of ATP13A2 in disease mutants relates to a combination of protein instability and abnormal intracellular localization. Moreover, here we provide the first biochemical evidence demonstrating that HSP-and some KRS-causing ATP13A2 mutations impair autophosphorylation activity, at least in part explaining their loss-of-function. All P-type transport ATPases couple the autophosphorylation reaction to the vectorial transport of (a) ligand(s) over biological membranes, indicating that the impaired autophosphorylation of ATP13A2 might reflect defective substrate transport. Alternatively, like other P-type ATPases (Pierre and Xie, 2006) , ATP13A2 may play a scaffolding role in signalling complexes, which might be regulated by autophosphorylation. Defects in one or both functionalities might be disease-causing.
The p.Thr512Ile mutation (HSP and KRS) impairs ATP13A2 autophosphorylation activity, which together with mistargeting of the mutant protein contributes to its loss of function. Thr512 is part of the highly conserved autophosphorylation motif ( 508 D-K-T-G-T), which is present in all P-type transport ATPases. Thr512 is positioned in the catalytic centre in between the autophosphorylation site Asp508 and the Mg 2+ binding residue Thr510. Similar to the Thr512Ile mutation in ATP13A2, the Thr512Ala mutation of the equivalent residue in the Ca 2+ -pump SERCA1a (Thr355), one of the archetypical P-type ATPases, also impairs autophosphorylation and substrate occlusion (McIntosh et al., 1999) , notably without affecting protein stability (Maruyama et al., 1989) .
The loss-of-autophosphorylation activity of the Gln1135 Ã mutant (HSP) might indicate that the C-terminus of ATP13A2 is functionally important, as is the case for other P-type ATPases (Vandecaetsbeek et al., 2009) . However, the low protein abundance and failure to exit the endoplasmic reticulum, rather suggests that this mutant is improperly folded and efficiently degraded. Indeed, the truncation of ATP13A2 at the border of the cytosolic end of transmembrane segment M10 might disturb the membrane topology.
Lysosomal and mitochondrial dysfunctions are common features in HSP and KRS
Why ATP13A2 loss-of-function is implicated in a spectrum of neuronal disorders remains unclear, but the deficiency of this late endo-/lysosomal P-type transporter triggers lysosomal abnormalities (Chen et al., 2011; Park et al., 2011; Dehay et al., 2012; Grunewald et al., 2012; Podhajska et al., 2012; Kong et al., 2014) . Fibroblasts derived from the Thr512Ile KRS patient are marked by general lysosomal dysfunction as observed by the accumulation of lysosomes, impaired autophagy, reduced lysosomal proteolysis and increased lysosomal pH (Dehay et al., 2012; Gusdon et al., 2012; Ramonet et al., 2012; . Here, we confirm in fibroblasts of unrelated HSP and KRS patients that LAMP1-positive organelles accumulate, correlating with a reduction in their proteolytic activity. Thus, an increased number of LAMP1-positive organelles may be a hallmark of ATP13A2 dysfunction. Ultrastructural analysis revealed deposition of abnormal lysosomal storage material in the form of lipid whorls and stacks of membranes. Interestingly, a similar lysosomal phenotype has previously been reported for three other subtypes of HSP: SPG11 (spatacsin), SPG15 (ZFYVE26/spastizin) and SPG48 (AP5Z1/ AP-5). In all three, accumulation of LAMP1-positive organelles was described in primary patient fibroblasts (Vantaggiato et al., 2013; Chang et al., 2014; Renvoise et al., 2014; Hirst et al., 2016) . Loss of SPG11/SPG15 results in the depletion of free lysosomes and an accumulation of autolysosomes due to impaired lysosome reformation, an mTOR dependent pathway . Furthermore, fibroblasts of patients with mutations in the SPG15-or SPG48 gene display multilamellar accumulation of membranous material similar to those we observe in ATP13A12 mutant fibroblasts (Renvoise et al., 2014; Hirst et al., 2016) . These findings therefore suggest a molecular link between these four HSP subtypes that is particularly interesting in light of the clinical and imaging overlap (see above). Neurons depend heavily on mitochondrial clearance pathways to preserve mitochondrial health, which on itself rests on efficient lysosomal function. Like lysosomal dysfunction, impaired mitochondrial function is implicated in NCL (Pezzini et al., 2011; Vidal-Donet et al., 2013) , HSP (Casari et al., 1998; Hansen et al., 2002; Patel et al., 2002; Verny et al., 2011; Arif et al., 2013) or KRS (Grunewald et al., 2012; Park et al., 2014) , and several studies connect ATP13A2 to mitochondrial clearance (Grunewald et al., 2012; Gusdon et al., 2012; Holemans et al., 2015; Martin et al., 2016) . Mitochondrial fragmentation and impaired ATP production were previously described in the Thr512Ile-KRS fibroblasts (Grunewald et al., 2012) . Although we did not observe significant changes in the morphology of the mitochondrial network in the fibroblasts of either the HSP or KRS patients, the reduction in the mitochondrial membrane potential suggests impaired mitochondrial functionality that may result in lower ATP levels. Moreover, the increased mitochondrial mass might point to an impaired mitochondrial clearance, which might be connected to the ATP13A2-mediated lysosomal dysfunction. In fact, ATP13A2 has been implicated in autophagy pathways (Dehay et al., 2012; Grunewald et al., 2012; Podhajska et al., 2012; and also the activation of ATP13A2 by the phospholipids phosphatidic acid and phosphatidylinositol(3,5)bisphosphate suggests a role in autophagy Martin et al., 2015) . Interestingly, genetic defects in the pathways controlling phospholipid homeostasis, like phosphatidic acid, have been previously implicated in HSP. Mutations in two phospholipases (DDHD1 and DDHD2) cause SPG28 and SPG52 HSP subtypes, respectively. Defects in these enzymes lead to lipid accumulation and disturbed intracellular trafficking (SchuursHoeijmakers et al., 2012; Tesson et al., 2012; Gonzalez et al., 2013) .
In conclusion, loss of ATP13A2 function causes a combination of lysosomal and mitochondrial dysfunction that affects multiple neuronal populations. This translates to a spectrum of neurological disorders ranging from complicated HSP to KRS. We propose that patients with complicated HSP should be routinely tested for ATP13A2 mutations, in particular if complicated by progressive cognitive and cerebellar dysfunction. 
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